Literature DB >> 16389455

Sonic Hedgehog signaling in advanced prostate cancer.

S Datta1, M W Datta.   

Abstract

The Hedgehog family of growth factors activate a highly conserved signaling system for cell-cell communication that regulates cell proliferation and differentiation during development. Abnormal activation of the Hedgehog pathway has been demonstrated in a variety of human tumors, including those of the skin, brain, lung and digestive tract. Hedgehog pathway activity in these tumors is required for cancer cell proliferation and tumor growth. Recent studies have uncovered the role for Hedgehog signaling in advanced prostate cancer and demonstrated that autocrine signaling by tumor cells is required for proliferation, viability, and invasive behavior. The level of Hedgehog activity correlates with the severity of the tumor and is both necessary and sufficient for metastatic behavior. Blockade of Hedgehog signaling leads to tumor shrinkage and remission in preclinical tumor xenograft models. Thus, Hedgehog signaling represents a novel pathway in prostate cancer that offers opportunities for prognostic biomarker development, drug targeting and therapeutic response monitoring.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389455     DOI: 10.1007/s00018-005-5389-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  37 in total

1.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

2.  Inhibition of Gli1-mediated prostate cancer cell proliferation by inhibiting the mTOR/S6K1 signaling pathway.

Authors:  Hong Yang; Libing Hu; Zhimin Liu; Yang Qin; Ruiqian Li; Guoying Zhang; Bin Zhao; Chengwei Bi; Yonghong Lei; Yu Bai
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

Review 3.  Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

Review 4.  Skp2: a novel potential therapeutic target for prostate cancer.

Authors:  Zhiwei Wang; Daming Gao; Hidefumi Fukushima; Hiroyuki Inuzuka; Pengda Liu; Lixin Wan; Fazlul H Sarkar; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2011-09-22

5.  Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth.

Authors:  Maribella Domenech; Robert Bjerregaard; Wade Bushman; David J Beebe
Journal:  Integr Biol (Camb)       Date:  2012-01-11       Impact factor: 2.192

Review 6.  Desire, disease, and the origins of the dopaminergic system.

Authors:  Roy V Sillitoe; Michael W Vogel
Journal:  Schizophr Bull       Date:  2008-02-17       Impact factor: 9.306

7.  Sonic Hedgehog pathway activity in prostate cancer.

Authors:  Olga Bragina; Natalja Njunkova; Svetlana Sergejeva; Lilian Järvekülg; Priit Kogerman
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

8.  Genetic interaction screens identify a role for hedgehog signaling in Drosophila border cell migration.

Authors:  Erika R Geisbrecht; Ketki Sawant; Ying Su; Ze Cindy Liu; Debra L Silver; Ashley Burtscher; Xuejiao Wang; Alan Jian Zhu; Jocelyn A McDonald
Journal:  Dev Dyn       Date:  2013-02-08       Impact factor: 3.780

Review 9.  Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.

Authors:  Kathryn D Rodgers; James D San Antonio; Olena Jacenko
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

Review 10.  Prostate cancer and Hedgehog signalling pathway.

Authors:  L M Antón Aparicio; R García Campelo; J Cassinello Espinosa; M Valladares Ayerbes; M Reboredo López; S Díaz Prado; G Aparicio Gallego
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.